Pharmsynthez to build a large-scale plant for cancer drug production in Moscow

17 February 2025

Pharmsynthez, one of Russia’s largest drugmakers, will build a large-scale plant for the production of anticancer drugs in the city of Moscow by 2026.

Under the terms of the project, the new plant will be built in the Alabushevo site of the city of Zelenograd, while most of its future output will be supplied for the needs of the city of Moscow, as part of the earlier contract, signed between the sides.

The first supplies should begin in early 2026, while the plant itself is expected to be built and launched in 2025. The cost of the project is not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK